Imatinib Amarox

Imatinib, the active ingredient in Imatinib Amarox, is a tyrosine kinase inhibitor presented as a tablet for oral use. It targets specific molecular pathways that drive malignant cell growth and is employed in the treatment of certain blood cancers and gastrointestinal tumors.

GNH USA supplies Imatinib Amarox as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, transplant units and pharmacies worldwide, ensuring quality‑assured products and reliable logistics for cancer care programs. The company adheres to stringent regulatory standards and provides comprehensive support for product registration and distribution.

Imatinib is a targeted therapy that inhibits specific tyrosine kinases involved in certain hematologic malignancies and solid tumors. - Chronic myeloid leukemia (CML): reduces leukemic cell proliferation and induces remission in patients with BCR‑ABL positive disease. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): achieves molecular remission by blocking BCR‑ABL signaling in lymphoid blasts. - Gastrointestinal stromal tumor (GIST): suppresses c‑KIT driven tumor growth, leading to disease stabilization and tumor shrinkage.